InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,780.05
(
-0.21%
)
US TECH 100
19,727.60
(
0.01%
)
Dow Jones
42,454.12
(
-0.14%
)
Brent Oil
78.81
(
-0.32%
)
Bitcoin
60,579.97
(
0.51%
)
Post# of 253340
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Mufaso

Send PM Follow Ignore
Followers 37
Posts 567
Boards Moderated 0
Alias Born 01/08/2008

Mufaso

Member Level

Re: Mufaso post# 250860

Friday, 03/01/2024 9:04:53 AM

Friday, March 01, 2024 9:04:53 AM

Post# of 253340
Viking Therapeutics price target raised to $120 from $38 at Truist 07:31 VKTX

Truist raised the firm's price target on Viking Therapeutics to $120 from $38 and keeps a Buy rating on the shares. The firm is citing "further evidence" of VK2735 being a"best in class" GLP-1 weight loss drug profile. VK2735 appears to be about twice as effective in weight loss compared to tirzepatide and numerically superior to even retatrutide, a triple agonist, all the while exhibiting superior tolerability, the analyst tells investors in a research note.



Read more at:
https://thefly.com/n.php?id=3874637

"People are best convinced by reasons they discover themselves"

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up